An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Fidanacogene Elaparvovec (Beqvez): CADTH Reimbursement Recommendation: Indication: For the treatment of adults (aged 18 years or older) with moderately severe to severe hemophilia B (congenital Factor IX deficiency) who are negative for neutralizing antibodies to variant AAV serotype Rh74 [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar.
Top results in this bookTable of Contents
Etranacogene Dezaparvovec (Hemgenix): CADTH Reimbursement Recommendation: Indication: For treatment of adults (aged 18 years of age or older) with Hemophilia B (congenital factor IX deficiency) who require routine prophylaxis to prevent or reduce the frequency of bleeding episodes [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 May.
Regulatory Processes for Rare Disease Drugs in the United States and European Union: Flexibilities and Collaborative Opportunities.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions in the United States and the European Union; Shore CK, Worku TL, Smith CW, et al., editors.
Washington (DC): National Academies Press (US); 2024 Oct 30.
CADTH Reimbursement Reviews and Recommendations.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013-.
Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action; Martinez RM, Osei-Anto HA, McCormick M, editors.
Washington (DC): National Academies Press (US); 2020 Sep 10.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on